SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Corriente Advisors, LLC

CIK 0001406718 · 1401 FOCH ST, SUITE 100, FORT WORTH, TX, 76107 · 8178700400

Reported Value
$93M
Q1 2020
Positions
11
Filings on Record
17
2020–present window
Filed
May 18, 2020
original filing

Summary

Corriente Advisors, LLC reported $93M in U.S.-listed holdings across 11 positions for Q1 2020.

The portfolio is heavily concentrated: Reata Pharmaceuticals alone accounts for 29.6% of reported value.

Compared with Q4 2019, the fund opened 6 new positions and exited 12.

Portfolio Metrics

Turnover
+27.7%
vs prior filed quarter
Top-10 Concentration
+98.9%
share of reported value
Largest Position
+29.6%
Reata Pharmaceuticals
New / Exited
6 / 12
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $186MQ4 ’19Q1 ’20: $93MQ2 ’20: $154MQ2 ’20Q3 ’20: $197MQ4 ’20: $420MQ4 ’20Q1 ’21: $272MQ2 ’21: $185MQ2 ’21Q3 ’21: $52MQ4 ’21: $12MQ4 ’21Q1 ’22: $268MQ2 ’22: $237MQ2 ’22Q3 ’22: $90MQ4 ’22: $0Q4 ’22Q1 ’23: $976,400Q2 ’23: $10,872Q2 ’23Q4 ’23: $10Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 76.8%Other: 18.7%ETP: 4.5%
  • Common Stock · 76.8% · $71M
  • Other · 18.7% · $17M
  • ETP · 4.5% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GBTCGRAYSCALE BITCOIN ORDNEW+590.0K590.0K+$4M$4M
PIERIS PHARMACEUTICALS INCNEW+1.78M1.78M+$4M$4M
EPIZYME INCNEW+230.0K230.0K+$4M$4M
SDGRSCHRODINGER ORDNEW+60.0K60.0K+$3M$3M
SUNESIS PHARMACEUTICALS INCNEW+3.02M3.02M+$1M$1M
TSLATESLA INCNEW+2.0K2.0K+$1M$1M
APTOSE BIOSCIENCES INCADDED+2.46M2.92M+$15M$17M
CUE BIOPHARMA INCADDED+535.0K820.0K+$7M$12M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

11 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1REATA PHARMACEUTICALS INCCL A29.60%$27M190.0K
2MAXAR TECHNOLOGIES INCCOM19.47%$18M1.69M
3APTOSE BIOSCIENCES INCCOM NEW18.71%$17M2.92M
4CUE BIOPHARMA INCCOM12.56%$12M820.0K
5GBTCGRAYSCALE BITCOIN ORDhistory →COM4.53%$4M590.0K
6PIERIS PHARMACEUTICALS INCCOM4.39%$4M1.78M
7EPIZYME INCCOM3.85%$4M230.0K
8SDGRSCHRODINGER ORDhistory →COM2.79%$3M60.0K
9BLUBELLUS HEALTH INC NEWhistory →COM NEW1.60%$1M148.7K
10SUNESIS PHARMACEUTICALS INCCOM1.35%$1M3.02M
11TSLATESLA INChistory →COM1.13%$1M2.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$10M3Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review7Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$10,8722Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$976,4002May 10, 202313F-HRchanges · EDGAR ↗
Q4 2022$01Feb 15, 202313F-HRchanges · EDGAR ↗
Q3 2022$90M5Nov 15, 202213F-HRchanges · EDGAR ↗
Q2 2022$237M5Aug 16, 202213F-HRchanges · EDGAR ↗
Q1 2022$268M5May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$12M3Feb 15, 202213F-HRchanges · EDGAR ↗
Q3 2021$52M8Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$185M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$272M10May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$420M19Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$197M16Nov 3, 202013F-HRchanges · EDGAR ↗
Q2 2020$154M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$93M11May 18, 202013F-HRchanges · EDGAR ↗
Q4 2019$186M17Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.